OBJECTIVE: To ascertain the age and gender distribution of patients receiving anticoagulant (AC) treatment with warfarin, and to establish the prevalence of AC treatment and its indications among the Finnish population. DESIGN: A cross-sectional study in which the patients were identified from the patient records of health centres. SETTING: Primary health care in the Hospital District of South Ostrobothnia in Finland. PATIENTS: Those inhabitants of 15 municipalities in the study area who received AC treatment with warfarin on 1 April 2004. The total number of inhabitants was 132 621 at the end of 2003. MAIN OUTCOME MEASURES: Patient age and gender distributions, the prevalence of AC treatment in the study area, and indications for AC treatment. RESULTS: Altogether 2389 patients were identified, 51.4% of them men. The mean age of the patients was 72.4 years. The prevalence of AC treatment was 1.8%; when age-adjusted to match the Finnish population it was 1.64%. The proportion of men receiving AC treatment was higher than that of women in all age groups. Atrial fibrillation (AF) was the most common main (60.2%) and second (7.2%) indication for AC treatment. CONCLUSION: Compared with Finnish figures 12 years earlier the prevalence of AC treatment has more than doubled, and the proportion of AF among indications has increased from 47% to 67%. New current care guidelines on AF and the increasing proportion of the elderly among the population are probable explanations.
OBJECTIVE: To ascertain the age and gender distribution of patients receiving anticoagulant (AC) treatment with warfarin, and to establish the prevalence of AC treatment and its indications among the Finnish population. DESIGN: A cross-sectional study in which the patients were identified from the patient records of health centres. SETTING: Primary health care in the Hospital District of South Ostrobothnia in Finland. PATIENTS: Those inhabitants of 15 municipalities in the study area who received AC treatment with warfarin on 1 April 2004. The total number of inhabitants was 132 621 at the end of 2003. MAIN OUTCOME MEASURES: Patient age and gender distributions, the prevalence of AC treatment in the study area, and indications for AC treatment. RESULTS: Altogether 2389 patients were identified, 51.4% of them men. The mean age of the patients was 72.4 years. The prevalence of AC treatment was 1.8%; when age-adjusted to match the Finnish population it was 1.64%. The proportion of men receiving AC treatment was higher than that of women in all age groups. Atrial fibrillation (AF) was the most common main (60.2%) and second (7.2%) indication for AC treatment. CONCLUSION: Compared with Finnish figures 12 years earlier the prevalence of AC treatment has more than doubled, and the proportion of AF among indications has increased from 47% to 67%. New current care guidelines on AF and the increasing proportion of the elderly among the population are probable explanations.
Authors: M Viitaniemi; K Eskola; H Kurunmäki; A Latva-Nevala; A M Wallin; M Paloneva; I Virjo; S Ylinen; S Ohman; M Isokoski Journal: Scand J Prim Health Care Date: 1999-03 Impact factor: 2.581
Authors: Heikki Lamminen; Samuli Niiranen; Kirsi Niemi; Heikki Mattila; Seppo Kalli Journal: Scand J Prim Health Care Date: 2002-06 Impact factor: 2.581
Authors: Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang Journal: Circulation Date: 2006-07-03 Impact factor: 29.690
Authors: K Eskola; P Aittoniemi; H Kurunmäki; A Latva-Nevala; M Paloneva; A M Wallin; M Viitaniemi; I Virjo; S Ylinen; S Ohman; M Isokoski Journal: Scand J Prim Health Care Date: 1996-09 Impact factor: 2.581
Authors: Jenni Ilomäki; Arja Helin-Salmivaara; Risto Huupponen; Maria Rikala; Carl M Kirkpatrick; Maarit Jaana Korhonen Journal: Eur J Clin Pharmacol Date: 2015-04-26 Impact factor: 2.953
Authors: Daniel K Nishijima; Steven R Offerman; Dustin W Ballard; David R Vinson; Uli K Chettipally; Adina S Rauchwerger; Mary E Reed; James F Holmes Journal: Ann Emerg Med Date: 2012-06 Impact factor: 5.721
Authors: Maria Rikala; Helena Kastarinen; Pekka Tiittanen; Risto Huupponen; Maarit Jaana Korhonen Journal: Clin Epidemiol Date: 2016-02-05 Impact factor: 4.790